Skip to main content
OMDAOmada Health, Inc.Sell6.3·$11.87
SellModerate Confidence
Investment thesis

Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.

Thesis pillars

  • Strong Revenue Growth→Stable
  • Overbought Late Cycle Risk↑Improving
  • Notable Insider Selling↑Improving
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 6, 2026· older than 90 days

Full reasoning →

Open full analysis

Omada Health, Inc. (OMDA) Stock Analysis

Inst Constrain edge

SellGrowthModerate Confidence

Healthcare · Health Information Services

Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum.

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more

$11.87+94.2% A.UpsideScore 6.3/10#3 of 22 Health Information Services
QualityF-score9 / 9FCF yield2.30%
Stop $11.41Analyst target $23.05(−13% haircut)A.R:R 6.3:1
Analyst consensus$26.50+123.3%12 analysts with price targets
$23.05Analyst target
$11.87price
$26.50mean
$35

Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 102d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Oct 29, 2026

Recent Developments — Omada Health, Inc.

Latest item Oct 29, 2026 · Generated 2026-11-22T11:32:08Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 4, 2027102d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Risk below floor (1.6 < 2.5)

Key Metrics

P/E (TTM)29.7
P/E (Fwd)17.2
Mkt Cap$736M
EV/EBITDA37.7
Profit Mgn4.2%
ROE5.7%
Rev Growth34.2%
Beta—
DividendNone
Analysts with ratings18

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C1.44bearish
IV85%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerlimited number of customers and channel partners
    10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
  • MEDIUMSupplierlimited number of third-party suppliers
    10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Volatile — 9.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Implied Vol
0.0
Days To Cover
1.9
Short Interest
2.5
Put Call
3.7
High short interest: 15%High IV: 85%Concentration risks: 2 MED (10-K Item 1A)

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.0
Volume
4.7
Capitulation risk (RSI 20, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.5%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.2<4.5INSIDER 0.23%=MODERATEA.R:R 6.3 ≥ 1.5No SEC red flagsEARNINGS PROXIMITY 102d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
20 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $11.76Resistance $19.91

Price Targets

$11
$23
A.Upside+94.2%
A.R:R6.3:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Risk below floor (1.6 < 2.5)
! momentum at 2.2 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-03-04 (102d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OMDA stock a buy right now?

Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.41. Score 6.3/10, moderate confidence.

What is the OMDA stock price target?

Analyst target: $23.05 (+94.2% upside). Prior stop was $11.41. Stop-loss: $11.41.

What are the risks of investing in OMDA?

Risk below floor (1.6 < 2.5).

Is OMDA overvalued or undervalued?

Omada Health, Inc. trades at a P/E of 29.7 (forward 17.2). TrendMatrix value score: 7.0/10. Verdict: Sell.

What do analysts say about OMDA?

18 analysts rate OMDA, with a consensus score of 4.0/5. 12 analysts publish price targets averaging $27.

What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

Related stocks: WAY (Waystar Holding Corp.) · CTEV (Claritev Corporation) · EVH (Evolent Health, Inc) · HTFL (Heartflow, Inc.) · SOPH (SOPHiA GENETICS SA)
Home › Stocks › OMDA

Latest news

Latest News

Moomoo25d ago
MarketBeat95d ago
MarketBeat95d ago
MarketBeat102d ago
MarketBeat102d ago
Investing.com102d ago
MarketBeat102d ago
Seeking Alpha102d agoEarnings
MarketBeat102d agoAnalyst
Investing.com Nigeria26d ago
MarketBeat96d ago
MarketBeat103d ago
Investing.com India103d agoAnalyst
TradingView24d agoEarnings
The Globe and Mail101d agoAnalyst
Yahoo Finance105d ago
MarketBeat99d ago
MarketBeat106d agoAnalyst
Sahm106d agoEarnings
Https://www.dars.gov.et/27d ago
Loading more...